520 related articles for article (PubMed ID: 35228265)
1. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
2. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.
Jung JY; Ryu HJ; Lee SH; Kim DY; Kim MJ; Lee EJ; Ryu YM; Kim SY; Kim KP; Choi EY; Ahn HJ; Chang S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685714
[TBL] [Abstract][Full Text] [Related]
3. Stimuli-responsive magnetic silica-poly-lactic-co-glycolic acid hybrid nanoparticles for targeted cancer chemo-immunotherapy.
Gupta A; Niveria K; Chandpa HH; Singh M; Kumar V; Panda AK; Meena J
Drug Deliv Transl Res; 2024 Feb; ():. PubMed ID: 38347431
[TBL] [Abstract][Full Text] [Related]
4. PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth.
Kwak SY; Lee S; Han HD; Chang S; Kim KP; Ahn HJ
Mol Pharm; 2019 Dec; 16(12):4940-4953. PubMed ID: 31651174
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models.
Karoon Kiani F; Izadi S; Ansari Dezfouli E; Ebrahimi F; Mohammadi M; Chalajour H; Mortazavi Bulus M; Nasr Esfahani M; Karpisheh V; Mahmoud Salehi Khesht A; Abbaszadeh-Goudarzi K; Soleimani A; Gholizadeh Navashenaq J; Ahmadi M; Hassannia H; Hojjat-Farsangi M; Shahmohammadi Farid S; Hashemi V; Jadidi-Niaragh F
Life Sci; 2022 Jan; 288():120166. PubMed ID: 34813798
[TBL] [Abstract][Full Text] [Related]
6. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
[TBL] [Abstract][Full Text] [Related]
7. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
8. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
9. Stearyl polyethylenimine complexed with plasmids as the core of human serum albumin nanoparticles noncovalently bound to CRISPR/Cas9 plasmids or siRNA for disrupting or silencing PD-L1 expression for immunotherapy.
Cheng WJ; Chen LC; Ho HO; Lin HL; Sheu MT
Int J Nanomedicine; 2018; 13():7079-7094. PubMed ID: 30464460
[TBL] [Abstract][Full Text] [Related]
10. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells.
Heo MB; Cho MY; Lim YT
Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
[TBL] [Abstract][Full Text] [Related]
12. T-cell engaging poly(lactic-co-glycolic acid) nanoparticles as a modular platform to induce a potent cytotoxic immunogenic response against PD-L1 overexpressing cancer.
Duwa R; Pokhrel RH; Banstola A; Pandit M; Shrestha P; Jeong JH; Chang JH; Yook S
Biomaterials; 2022 Dec; 291():121911. PubMed ID: 36399833
[TBL] [Abstract][Full Text] [Related]
13. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
15. Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
Bastaki S; Aravindhan S; Ahmadpour Saheb N; Afsari Kashani M; Evgenievich Dorofeev A; Karoon Kiani F; Jahandideh H; Beigi Dargani F; Aksoun M; Nikkhoo A; Masjedi A; Mahmoodpoor A; Ahmadi M; Dolati S; Namvar Aghdash S; Jadidi-Niaragh F
Life Sci; 2021 Feb; 266():118847. PubMed ID: 33309720
[TBL] [Abstract][Full Text] [Related]
16. Co-immunizing with PD-L1 induces CD8
Guo S; Xiao P; Li B; Wang W; Wang S; Lv T; Xu X; Chen C; Huang L; Li Z; Tang L; Peng L; Wang H
Int Immunopharmacol; 2020 Jul; 84():106516. PubMed ID: 32334387
[TBL] [Abstract][Full Text] [Related]
17. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.
Lee CK; Atibalentja DF; Yao LE; Park J; Kuruvilla S; Felsher DW
Nanotheranostics; 2022; 6(3):243-255. PubMed ID: 35145835
[No Abstract] [Full Text] [Related]
19. Aptamer-functionalized targeted siRNA delivery system for tumor immunotherapy.
Lv H; Wang T; Ma F; Zhang K; Gao T; Pei R; Zhang Y
Biomed Mater; 2022 Feb; 17(2):. PubMed ID: 35147520
[TBL] [Abstract][Full Text] [Related]
20. Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
Cai S; Chen Z; Wang Y; Wang M; Wu J; Tong Y; Chen L; Lu C; Yang H
Theranostics; 2021; 11(4):1970-1981. PubMed ID: 33408792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
